Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOKNASDAQ:EYENNASDAQ:MRKRNASDAQ:STSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$2.71+0.6%$3.06$1.94▼$12.32$4.06M-0.04124,786 shs25,028 shsEYENEyenovia$15.96+51.1%$3.99$0.85▼$124.80$45.97M2.471.25 million shs4.63 million shsMRKRMarker Therapeutics$1.58+0.4%$1.36$0.95▼$5.99$18.10M1.4379,933 shs33,364 shsSTSASatsuma Pharmaceuticals$1.10$1.08$0.59▼$8.08$36.47M0.1701,788 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%+2.85%-22.49%+20.22%-57.89%EYENEyenovia0.00%+46.69%+667.31%+1,562.33%-74.03%MRKRMarker Therapeutics0.00%+7.95%+4.37%+55.89%-69.63%STSASatsuma Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AEYENEyenovia1.0433 of 5 stars1.05.00.00.03.00.00.6MRKRMarker Therapeutics3.2286 of 5 stars3.83.00.03.90.00.80.6STSASatsuma PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 0.00N/AN/AN/AEYENEyenovia 2.00Hold$2.00-87.47% DownsideMRKRMarker Therapeutics 3.50Strong Buy$13.17735.45% UpsideSTSASatsuma Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$10.25M0.39N/AN/A$4.74 per share0.57EYENEyenovia$60K766.08N/AN/A($695.52) per share-0.02MRKRMarker Therapeutics$6.59M2.70N/AN/A$1.73 per share0.91STSASatsuma PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)EYENEyenovia-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)STSASatsuma Pharmaceuticals-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/ALatest EVOK, EYEN, STSA, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025EYENEyenovia-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/AEYENEyenoviaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ASTSASatsuma PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.551.50EYENEyenoviaN/A0.340.34MRKRMarker TherapeuticsN/A6.796.79STSASatsuma PharmaceuticalsN/A7.447.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AEYENEyenovia25.84%MRKRMarker Therapeutics22.39%STSASatsuma Pharmaceuticals93.26%Insider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%EYENEyenovia7.10%MRKRMarker Therapeutics14.50%STSASatsuma Pharmaceuticals31.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.49 million1.46 millionNot OptionableEYENEyenovia402.88 million2.68 millionOptionableMRKRMarker Therapeutics6011.31 million9.67 millionNot OptionableSTSASatsuma Pharmaceuticals2133.15 million22.81 millionNot OptionableEVOK, EYEN, STSA, and MRKR HeadlinesRecent News About These CompaniesSatsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific MeetingJune 19, 2025 | prnewswire.comDurham-based Satsuma wins FDA approval for migraine treatmentMay 21, 2025 | ncbiotech.orgNNon-Postoperative Acute Pain Market Poised for Significant Expansion by 2034, Amid FDA Approvals and Innovative Therapeutic Pipeline | DelveInsightMay 16, 2025 | theglobeandmail.comFDA approves Atzumi for acute migraine treatment in adultsMay 6, 2025 | healio.comHFDA Okays Dihydroergotamine Nasal Spray for Acute MigraineMay 5, 2025 | medscape.comMNasal Powder for Acute Migraine Gets FDA NodMay 2, 2025 | msn.comFDA clears Satsuma’s Atzumi for migraineMay 2, 2025 | bioworld.comBSatsuma Pharmaceuticals Announces U.S. FDA Approval for AtzumiMay 1, 2025 | contractpharma.comCSatsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of MigraineApril 30, 2025 | prnewswire.comSatsuma Pharmaceuticals Inc (STSA)April 10, 2025 | uk.investing.comSatsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without AuraNovember 26, 2024 | prnewswire.comSNBL’s Subsidiary Resubmits Migraine Drug ApplicationOctober 31, 2024 | markets.businessinsider.comSatsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without AuraOctober 30, 2024 | prnewswire.comAprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comSatsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS DrugsOctober 8, 2024 | prnewswire.comSatsuma, AL Weather ConditionsAugust 21, 2024 | wunderground.comWSatsuma pulped as acute migraine drug flunks phase 3 trialAugust 9, 2024 | pharmaphorum.comPSatsuma, FL Weather ConditionsJuly 29, 2024 | wunderground.comWSatsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific MeetingJune 13, 2024 | prnewswire.comWith manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal sprayJanuary 18, 2024 | fiercepharma.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, EYEN, STSA, and MRKR Company DescriptionsEvoke Pharma NASDAQ:EVOK$2.70 +0.02 (+0.56%) Closing price 07/3/2025 01:25 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Eyenovia NASDAQ:EYEN$15.96 +5.40 (+51.14%) Closing price 07/2/2025 07:59 PM EasternExtended Trading$15.96 0.00 (0.00%) As of 07/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Marker Therapeutics NASDAQ:MRKR$1.58 +0.01 (+0.38%) As of 07/3/2025 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Satsuma Pharmaceuticals NASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
